Economic news

Indian Shares Muted as Oil, Outflows Offset IT Rebound

Oct 14 (Reuters) - Indian shares were little changed in morning trade on Wednesday as a rebound paused, with rising oil prices and sustained ​foreign outflows weighing on sentiment while investors assess corporate earnings.

The ‌Nifty 50 added 0.07% to 22,738.05, while the BSE Sensex edged 0.13% higher to 73,128.50 as of 09:46 a.m. IST. They swung between 0.2% gains and 0.2% losses ​in morning trade.

Eight of the 16 major sectors logged losses. The ​broader small-caps and mid-caps were little changed.

IT index, which gained ⁠5.2% in the previous session, added 1.2% on the day.

Both the ​Nifty and Sensex climbed about 1.6% on Tuesday, led by information technology stocks after ​HCLTech's quarterly profit beat expectations.

"Despite the sharp rebound, persistent macroeconomic uncertainties continue to warrant a cautious approach from investors," said Ajit Mishra, senior vice president of research at Religare Broking.

Oil ​prices rose to about $107 a barrel as traders weighed supply risks ​from fighting between Yemen's Iran-allied Houthis and Saudi Arabia against the prospect of increased diesel ‌supplies ⁠from Russia.

Foreign portfolio investors (FPI) remained net sellers of domestic stocks for the 13th consecutive session on Tuesday, taking the year-to-date outflows to a record $32.52 billion.

"The market has officially entered an 'earnings override' regime, while bias is neutral to ​rangebound, the undertone ​is cautious below ⁠23,000 for the Nifty," said Hemang Gor, senior research analyst of derivatives and technical research at Axis Direct.

Among ​stocks, Tata Elxsi climbed 7.8% after the engineering research and development ​firm posted ⁠higher quarterly profit, supported by growth in its transportation and media segments.

Bharat Coking Coal jumped 6.6% after the company hiked basic prices of certain grades of ⁠raw ​coking coal for the non-regulated sector.

Zydus Lifesciences lost ​1.5% after US drug regulator concluded an inspection at the pharmaceutical company's manufacturing plant in Ahmedabad with five ​observations.

Reporting by Bharath Rajeswaran in Bengaluru; Editing by Sherry Jacob-Phillips and Janane Venkatraman

Source: Reuters


To leave a comment you must or Join us


More news


Back to economic news list

By visiting our website and services, you agree to the conditions of use of cookies. Learn more
I agree